Abstract:Since March 2018, China has conducted five rounds of negotiations for the inclusion of drugs in the medical insurance system and implemented eight batches of centralized drug procurement. The role of the medical insurance department as a strategic purchaser in the pharmaceutical market has been continuously strengthened, playing a crucial role in controlling the unreasonable growth of medical expenses and reducing the economic burden on patients. The policy of centralized drug procurement, by exchanging quantity for price, can significantly reduce drug prices and lower the profit level of companies. However, being included in the centralized drug procurement catalog can bring a substantial and stable market share to the winning companies. Therefore, the impact of the centralized drug procurement policy on the operational performance of winning companies and how their business decisions should be adjusted remain to be thoroughly explored from both theoretical and empirical perspectives. To assess the impact of the centralized drug procurement policy on the operational performance of companies, this study takes publicly listed pharmaceutical manufacturing companies from 2016 to 2020 as the sample and conducts empirical analysis using methods such as difference in difference (propensity score) matching (PSM-DID). The results showed that the centralized volume-based procurement of drugs policy had a significant negative impact on the business performance of bidding listed pharmaceutical manufacturing companies, indicating that the increase in the sales of bidding drugs could not fully make up for the profit loss caused by the price reduction in the short term. Pharmaceutical manufacturing companies should further adjust their market competition strategies, actively engage in research and development innovation. The government should guide pharmaceutical companies to improve their operational performance while ensuring the quality of drug supply by optimizing the supporting innovative incentive policies in the centralized drug procurement policy.

Can Government Procurements Improve Companies’ Financial Efficiency——Evidence from Chinese Listed Companies Chinese Full Text

Government intervention and corporate M & A transactions : Evidence from China

Political Connections And Loan Availability: Evidence From Chinese Private Firms

Can government guided funds alleviate corporate financing constraints? Evidence from China

Does government procurement affect corporate carbon emissions? Evidence from China

On College Government Procurement Management in Financial Crisis

Government procurement and zombie firms' productivity: Evidence from China

Government Background Customers and Private Enterprise Innovation from the Perspective of Supply Chain Risk Transmission

Green public procurement and corporate environmental performance: An empirical analysis based on data from green procurement contracts

Public procurement, corporate social responsibility and green innovation: evidence from china

Reflections on the Government‘s Purchasing Public Service

Research on the Influence of Government Subsidy on New Quality Productive Forces of Grain Enterprises - Empirical Evidence from Listed Companies in China

Effects of public procurement on corporate total-factor carbon productivity: evidence from China

Impact of supply chain finance on the performance of agricultural small and medium-sized enterprises: Evidence from Chinese listed companies

Impact Factors on the Conditions of Chinese Enterprises Attaining Government Subsidies: An Empirical Investigation Based on Data Base of Industrial Enterprises

Effect of centralized volume-based procurement of drugs on business performance of listed pharmaceutical enterprises

Driving force of value reversal in Chinese overleveraged firms: The mechanism and path of private placement

Government-initiated corporate social responsibility and performance growth—Evidence from enterprise engagement in targeted poverty alleviation in China

Government subsidies and corporate environmental, social and governance performance: Evidence from companies of China

Can companies get more government subsidies through improving their ESG performance? Empirical evidence from China

Government green procurement policies and corporate green total factor productivity